Previous Close | 6.37 |
Open | 6.56 |
Bid | 6.79 x 1100 |
Ask | 6.90 x 1400 |
Day's Range | 6.53 - 7.02 |
52 Week Range | 4.02 - 43.12 |
Volume | |
Avg. Volume | 3,418,013 |
Market Cap | 663.674M |
Beta (5Y Monthly) | 1.62 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.44 |
Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.77 |
Subscribe to Yahoo Finance Plus to view Fair Value for FATE
BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, issued an open letter from the CEO to shareholders, detailing the Company’s recent activities. The full letter is published below: Dear GT Biopharma Shareholders, I am proud to say that we have made significant
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Fate Therapeutics...
In this article, we will take a look at the 12 cash-rich small cap stocks to invest in. To see more such companies, go directly to 5 Cash-Rich Small Cap Stocks To Invest In. In 2022, standard diversified portfolios suffered through their worst-performing year in a century. Despite the decline in markets this past year, […]